Dec 9, 2016
NCT02658929: Phase 1 - Study of bb2121 in BCMA-Expressing refractory Multiple Myeloma CRB-401
CRB-401 NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma Study CRB-401...
439
Dec 9, 2016
NCT02884102: MMRF Molecular Profiling Protocol - Multiple Myeloma Research Foundation
MMRF NCT02884102: MMRF Molecular Profiling Protocol Multiple Myeloma Research Foundation Sponsor: Multiple Myeloma Research Foundation...
256
Dec 3, 2016
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121
NCT02786511: Longterm Follow-up of Subjects Treated With bb2121 NCT02786511: Longterm Follow-up of Subjects Treated With bb2121 This is a...
177
Dec 13, 2014
NCT02181413: Phase 3 - TOURMALINE-MM3 -Oral Ixazomib Citrate (MLN9708) Maintenance in NDMM Post ASCT
TOURMALINE-MM3 A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous...
368
Dec 12, 2014
NCT02252172 : Phase 3 - Dara, Lena & Dex VS Len & Dex in previously untreated Myeloma - MAIA STUDY
The MAIA Study NCT02252172: Phase 3: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in...
491
Dec 11, 2013
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in NDMM or L C Amyloid
NCT01864018: Phase 1/2: Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic...
67
Dec 6, 2013
NCT01850524: Phase 3 - TOURMALINE-MM2 - Oral Ixazomib + Lenalidomide/Dex Vs Placebo + Len/Dex NDMM
TOURMALINE-MM2 IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With...
134
Dec 9, 2011
NCT01454297: MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma - (CoMMpass)
MMRF CoMMpass Study Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile (CoMMpass) The primary...
842
Dec 1, 2011
NCT01415882: Phase 2: Ixazomib Citrate in Relapsed Multiple Myeloma, Not Refractory to Bortezomib
NCT01415882: Phase 2: Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib...
61
Dec 10, 2010
NCT01080391: Comparing Carfilzomib, Lenalidomide & Dex (CRd) vs Lenalidomide and Dex (Rd) - ASPIRE
THE ASPIRE TRIAL Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in...
537
Dec 30, 2008
NCT00644228 : Phase 3 - Lenalidomide and Dexamethasone + / - Bortezomib in NDMM - SWOG S0777
Phase III trial SWOG S0777 SWOG0777 0777 Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously...
402
Dec 14, 2008
NCT00689936: Phase 3 - Lenalidomide+low dose dex vs Melphalan, Prednisone, Thalidomide in NDMM FIRST
FIRST study IFM 07-01 CC-5013-MM020 Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan,...
440
Dec 21, 2007
NCT00507442: Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat NDMM EVOLUTION
EVOLUTION Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)...
108
Dec 14, 2007
NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
RRMM Relapsed and Refractory Multiple Myeloma NCT00511238: Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma...
91
Dec 7, 2007
NCT00478218: Phase 2 : Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating New Myeloma
NCT00478218: Phase 2 : Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma...
135
Dec 29, 2005
NCT00114101: Phase 3 - CALGB 100104 - Lenalidomide in Patients With MM Undergoing Auto Transplant
CALGB 100104 Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant NCT00114101: Phase 3 -...
426
Dec 11, 2003
NCT00056160 : Phase 3 - CC-5013 (lenalidomide) Dex Vs Dex Alone Previously Treated Multiple Myeloma
Multiple Myeloma (009) MM-009 NCT00056160 : Phase 3 - CC-5013 Plus Dex Versus Dex Alone in Previously Treated Subjects With Multiple...
148